Photo from wikipedia
Tyrosine kinase inhibitors (TKIs) have improved the outcome of patients with gastrointestinal stromal tumors (GISTs), but most patients eventually develop resistance and progress. Dasatinib is a potent inhibitor of BCR‐ABL,… Click to show full abstract
Tyrosine kinase inhibitors (TKIs) have improved the outcome of patients with gastrointestinal stromal tumors (GISTs), but most patients eventually develop resistance and progress. Dasatinib is a potent inhibitor of BCR‐ABL, KIT, and SRC family kinases as well as imatinib‐resistant cells. In GISTs, response evaluation is routinely done using computed tomography (CT) and 18F‐fluorodeoxyglucose positron emission tomography coupled to CT (FDG‐PET/CT) for early response assessment and outcome prediction.
Journal Title: Cancer
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!